针对性SEH治疗的新时代:从抑制到蛋白质降解的战略演变
Huizhi Yao1, Chang Liu1, Xin Zhou1
1Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi, China; Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China.
European journal of medicinal chemistry
|February 24, 2026
概括
可溶性环氧化酶 (sEH) 抑制剂增加有益的环氧化酸 (EETs) 用于治疗炎症,疼痛和心血管疾病. 研究重点是优化尿素/胺基基架和探索多位抑制剂以增强治疗效果.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 可溶性环氧化酶 (sEH) 调节内源性环氧化酸 (EETs).
- EETs具有抗炎,止痛,心血管保护和代谢调节作用.
- sEH是炎症,疼痛,代谢和神经退行性疾病的关键治疗点.
研究的目的:
- 总结sEH的生物功能和蛋白质特征.
- 审查开发sEH抑制剂的进展.
- 识别知识差距,并为sEH抑制剂开发提出一个翻译路线图.
主要方法:
- 关于sEH生物功能和抑制剂研究的文献综述.
- 分析目前用于sEH抑制剂设计的策略,包括脚手架优化和多目标方法.
- 识别诸如血脑屏障透性和探索新领域等挑战.
主要成果:
- 尿素和胺基基架的优化是开发活性和选择性SEH抑制剂的关键.
- 多位抑制剂 (例如,sEH/COX-2,sEH/PPARγ) 在协同作用方面正在迅速发展.
- 在天然产品中已经确定了结构多样化的sEH抑制剂.
结论:
- 需要对N端酸酶域 (sEH-P) 和改善血脑屏障透性进行进一步的研究.
- 解决这些知识差距对于将sEH抑制剂研究转化为临床应用至关重要.
- 提出了一个翻译路线图,以加快针对sEH的精准医学的发展.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
The Proteasome
1.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.8K
The Proteasome
10.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.4K
Regulated Protein Degradation
9.0K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.0K
Regulated Protein Degradation
3.2K
3.2K


